torcetrapib has been researched along with ezetimibe in 6 studies
| Studies (torcetrapib) | Trials (torcetrapib) | Recent Studies (post-2010) (torcetrapib) | Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) |
|---|---|---|---|---|---|
| 273 | 28 | 83 | 2,484 | 563 | 1,465 |
| Protein | Taxonomy | torcetrapib (IC50) | ezetimibe (IC50) |
|---|---|---|---|
| NPC1-like intracellular cholesterol transporter 1 | Homo sapiens (human) | 0.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansell, BJ | 1 |
| Lumley, T; Psaty, BM | 1 |
| Suckling, K | 1 |
| Rosenson, RS | 1 |
| Rizzoni, D; Rossi, GP | 1 |
| Blum, D; Chaput, E; Derks, M; Kallend, D; Niesor, EJ; Staempfli, A | 1 |
1 review(s) available for torcetrapib and ezetimibe
| Article | Year |
|---|---|
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Niacin; Quinolines | 2005 |
1 trial(s) available for torcetrapib and ezetimibe
| Article | Year |
|---|---|
Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Biomarkers; Cholestanol; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Cross-Over Studies; Desmosterol; Esters; Ezetimibe; Homeostasis; Humans; Intestinal Absorption; Lipid Metabolism; Male; Mesocricetus; Models, Animal; Phytosterols; Quinolines; Sitosterols; Sulfhydryl Compounds; Switzerland | 2011 |
4 other study(ies) available for torcetrapib and ezetimibe
| Article | Year |
|---|---|
Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.
Topics: Azetidines; Biomarkers; Clinical Trials as Topic; Drug Approval; Ezetimibe; Humans; Hypolipidemic Agents; Quinolines; Risk; United States; United States Food and Drug Administration | 2008 |
The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Design; Dyslipidemias; Ezetimibe; Humans; Quinolines | 2008 |
Functional assessment of HDL: Moving beyond static measures for risk assessment.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Ezetimibe; Glucose; Humans; Insulin; Lipase; Lipoproteins, HDL; Niacin; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds | 2010 |
Therapy: raising HDL cholesterol levels: a flight of Icarus?
Topics: Atherosclerosis; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Niacin; Quinolines | 2010 |